Frequency reconfigurable patch antenna for 4G LTE applications

A compact printed multi-band frequency reconfigurable patch antenna for 4G LTE applications is presented in this paper (50 x 60 x 1.6 mm3). The antenna consists of W-shaped and Inverted-U shaped patch lines connected in a Tree-shape on the front side of the antenna. The back-side of the antenna contains a 90°-tilted T-shaped strip connected with an Inverted-L shaped strip which is shorted with a patch on the front side for increasing the electrical length to cover lower frequency bands. Frequency reconfigurability is achieved by inserting three switches i.e., PIN diodes. The most critical part of this work is the designing of RLC-based DC line circuits for providing the DC biasing to the PIN diodes used as switches and inserting them at optimum locations. This antenna is reconfigurable among eight different 4G LTE frequency bands including 0.9 GHz, 1.4 GHz, 1.5 GHz, 1.6 GHz, 1.7 GHz, 1.8 GHz, 2.6 GHz, 3.5 GHz and WLAN band 2.5 GHz. The antenna exhibits different radiation patterns having a different direction of peak gain at different frequencies and for different switching combinations. The antenna is simulated with CST, and a prototype is fabricated to compare the measured and simulated results with good accuracy

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Background Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. Methods FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762. Findings Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839–1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26–6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38–2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months. Interpretation Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function. Funding UK Stroke Association and NIHR Health Technology Assessment Programme

Nickel toxicity in plants: Reasons, toxic effects, tolerance mechanisms, and remediation possibilities—a review

Nickel (Ni) is a naturally occurring metal, but anthropogenic activities such as industrialization, use of fertilizers, chemicals, and sewage sludge have increased its concentration in the environment up to undesirable levels. Ni is considered to be essential for plant growth at low concentration; however, Ni pollution is increasing in the environment, and therefore, it is important to understand its functional roles and toxic effects on plants. This review emphasizes the environmental sources of Ni, its essen-tiality, effects, tolerance mechanisms, possible remediation approaches, and research direction that may help in interdisciplinary studies to assess the significance of Ni toxicity. Briefly, Ni affects plant growth both positively and negatively, depending on the concentration present in the growth medium. On the positive side, Ni is essential for normal growth, enzymatic activities (e.g., urease), nitrogen metabolism, iron uptake, and specific metabolic reactions. On the negative side, Ni reduces seed germination, root and shoot growth, biomass accumulation, and final production. Moreover, Ni toxicity also causes chlorosis and necrosis and inhibits various physiological processes (photosynthesis, transpiration) and cause oxidative damage in plants. The threat associated with Ni is increased as Ni concentration increases day by day in the environment, particularly in soils; therefore, it would be hazardous for crop production in the near future. Additionally, the lack of information regarding the mechanisms of Ni tolerance in plants further intensifies this situation. Therefore, future research should be focused on approachable and prominent solutions in order to minimize the entry of Ni into our ecosystems

A Compact Triple-Band UWB Inverted Triangular Antenna with Dual-Notch Band Characteristics Using SSRR Metamaterial Structure for Use in Next-Generation Wireless Systems

A compact triple-band operation ultra-wideband (UWB) antenna with dual-notch band characteristics is presented in this paper. By inserting three metamaterial (MTM) square split-ring resonators (MTM-SSRRs) and a triangular slot on the radiating patch, the antenna develops measured dual-band rejection at 4.17–5.33 GHz and 6.5–8.9 GHz in the UWB frequency range (3–12 GHz). The proposed antenna offers three frequency bands of operation in the UWB range, which are between 3–4.17 GHz (~1.2 GHz bandwidth), 5.33–6.5 GHz (~1.17 GHz bandwidth), and 8.9–12 GHz (~3.1 GHz bandwidth), respectively. The higher resonating frequency band can be tuned/controlled by varying the width of the triangle slot, while the medium operational band can be controlled by adjusting the width of the SSRR slot. Initially, the simulated S-parameter response, 2D and 3D radiation patterns, gain, and surface current distribution of the proposed UWB inverted triangular antenna has been studied using epoxy glass FR4 substrate having parameters εr = 4.3, h = 1.6 mm, and tan δ = 0.025, respectively. In order to validate the simulation results, the proposed UWB antenna with dual-notch band characteristics is finally fabricated and measured. The fabricated antenna’s return-loss and far-field measurements show good agreement with the simulated results. The proposed antenna achieved the measured gain of 2.3 dBi, 4.9 dBi, and 5.2 dBi at 3.5 GHz, 6.1 GHz, and 9.25 GHz, respectively. Additionally, an in-depth comparative study is performed to analyze the performance of the proposed antenna with existing designs available in the literature. The results show that the proposed antenna is an excellent candidate for fifth-generation (5G) mobile base-stations, next-generation WiFi-6E indoor distributed antenna systems (IDAS), as well as C-band and X-band applications

Feasibility of reporting results of large randomised controlled trials to participants:experience from the Fluoxetine or Control under supervision (FOCUS) trial

Objectives Informing research participants of the results of studies in which they took part is viewed as an ethical imperative. However, there is little guidance in the literature about how to do this. The Fluoxetine Or Control Under Supervision trial randomised 3127 patients with a recent acute stroke to 6 months of fluoxetine or placebo and was published in the Lancet on 5 December 2018. The trial team decided to inform the participants of the results at exactly the same time as the Lancet publication, and also whether they had been allocated fluoxetine or placebo. In this report, we describe how we informed participants of the results.Design In the 6-month and 12-month follow-up questionnaires, we invited participants to provide an email address if they wished to be informed of the results of the trial. We re-opened our trial telephone helpline between 5 December 2018 and 31 March 2019.Setting UK stroke services.Participants 3127 participants were randomised. 2847 returned 6-month follow-up forms and 2703 returned 12-month follow-up forms; the remaining participants had died (380), withdrawn consent or did not respond.Results Of those returning follow-up questionnaires, a total of 1845 email addresses were provided and a further 50 people requested results to be sent by post. Results were sent to all email and postal addresses provided; 309 emails were returned unrecognised. Seventeen people replied, of whom three called the helpline and the rest responded by email.Conclusion It is feasible to disseminate results of large trials to research participants, though only around 60% of those randomised wanted to receive the results. The system we developed was efficient and required very little resource, and could be replicated by trialists in the future.Trial registration number ISRCTN83290762; Post-results